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SUMMARY
Intravenous fluid therapy has become a ubiquitous intervention in both human and veterinary 
medicine. The field of fluid therapy is characterised by numerous controversies, and despite their 
widespread use, fluids should be considered as drugs, as their use is associated with potential side 
effects and complications. This paper will review the differences between crystalloids and colloids, 
and how their clinical use has changed according to recent scientific evidence. Due to their 
theoretical advantages, hydroxyethyl starches (HES) have become the most commonly used colloids 
in both human and veterinary medicine. However, the results of human studies have revealed clear 
adverse effects on renal and haemostatic functions and an increase in mortality when comparing 
colloids versus crystalloids for fluid resuscitation. A quantitative toxicity has also been identified 
and excessive fluid resuscitation appears to be associated with an adverse outcome. These recent 
studies should prompt the veterinary profession to undertake an appraisal of current fluid therapy 
practices and recommendations that have thus far been largely based on theoretical benefits rather 
than clinical evidence. In this review we will focus on some common controversies and how our 
approach to fluid therapy may be adapted in light of the most recent veterinary and human data.
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Introduction
The first report in the medical literature of the intravenous 
administration of a salt-based solution was described 
in 1832 by Thomas Latta for the treatment of patients 
affected by cholera[1]. Since then, intravenous fluid therapy 
has become a ubiquitous intervention in both human 
and veterinary medicine and it represents a cornerstone 
in the treatment of ill patients. The field of fluid therapy 
EJCAP 24(2); Summer 2014, p14-p23
is characterised by numerous controversies regarding 
whether there are optimal fluid types, optimal doses and 
even whether there is a preferable timing and rate of fluid 
administration. Despite widespread use, fluid therapy is 
associated with potential side effects and complications, 
as recently revealed by the results of several large human 
randomised clinical trials [2,3,4]. These recent studies in the 
human field should prompt the veterinary profession to 
undertake an appraisal of current fluid therapy practices 
and recommendations that have been thus far largely 
based on theoretical benefits rather than clinical evidence. 
In this review we will focus on some common controversies 
and how our approach to fluid therapy may be adapted in 
light of the most recent veterinary and human data.
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Basic principles of fluid therapy
To be able to appreciate the nuances of fluid therapy 
a basic understanding of normal body fluid physiology 
is required. Total body water (TBW) accounts for 
approximately 60% of total body weight. Total body 
water is distributed between the intracellular fluid 
compartment (approximately 66%) and the extracellular 
fluid compartment (approximately 33%). These two 
spaces are separated by cell membranes. The extracellular 
fluid compartment is, in turn, further subdivided into an 
intravascular (8% TBW) and an interstitial space (25% 
TBW) [5], and these compartments are separated by the 
capillary wall (Figure 1). 
due to osmolarity gradients (osmotic pressure). Oncotic 
pressure, also known as colloid osmotic pressure, is a 
particular type of osmotic pressure that is generated by 
colloid molecules present in solutions. 
Clinical signs associated with fluid deficits vary accordingly 
to the compartment affected (Table 1). Dehydration is 
defined as total body water deficit, while hypovolemia 
indicates a purely intravascular volume deficit. The total 
intravascular volume, including both plasma and cellular 
components, is estimated to be approximately 88 ml/kg 
in dogs and 66 ml/kg in cats [6]. The intravascular volume, 
despite containing only a small proportion of the TBW, 
is the main determinant of cardiac preload and, as such, 
plays a fundamental role in maintaining cardiovascular 
stability. Preload, along with cardiac contractility and 
afterload, determines cardiac output and blood flow to 
peripheral tissues (perfusion). As a consequence of this, 
during hypovolemia, oxygen delivery to peripheral tissues 
is affected: when the metabolic needs of the body are 
no longer matched by the blood flow provided by the 
cardiovascular system, circulatory shock ensues. If left 
untreated circulatory shock will result in organ dysfunction 
and eventually death. Therefore, rapidly restoring and 
maintaining an effective intravascular volume is essential 
to reverse the progression of the shock state. This 
therapeutic intervention is referred to as fluid resuscitation 
and will be the main focus on this review. Other 
common reasons to administer fluids include restoration 
of the interstitial and intracellular fluid balance (i.e. 
rehydration), compensation for on-going fluid losses and 
to induce diuresis and maintain acid-base and electrolyte 
homeostasis.
Types of fluids
Fluids used in veterinary patients can be classified into 
Figure 1. Distribution of total body water (TBW) within the 
body showing the proportion allocated into the intracellular 
and extracellular fluid compartments. 
The barriers between fluid compartments have different 
permeability to different solutes based on size, charge 
and conformation. This selective permeability, along 
with hydrostatic and oncotic forces (i.e. Starling forces), 
determines the movement of fluids and electrolytes between 
compartments. Two other concepts that also play a role in 
the movement of fluid between compartments are osmolarity 
and oncotic pressure. Osmolarity is a measure of the number 
of particles present in a solution, independently of their size 
or weight. Water tends to distribute between compartments 
Table 1. Differentiation of hypoperfusion from dehydration via clinical signs
Signs consistent with hypoperfusion Signs consistent with dehydration
Increased heart rate Dry mucous membranes 
Hyperdynamic or hypodynamic pulses Prolonged skin tenting
Hypothermia or cold distal limbs Normal pulses
Prolonged capillary refill time Sunken eyeballs
Pale mucous membranes
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4 basic types: crystalloids, colloids, haemoglobin-based 
oxygen carriers and blood products [7]. Crystalloids are 
solutions of water and electrolytes or glucose. Some 
formulations might also contain buffers (e.g. lactate, 
acetate or gluconate) that, once administered, are 
metabolised to bicarbonate and can influence acid-
base balance. Crystalloids are classified into hypotonic, 
isotonic or hypertonic solutions based on their relative 
osmolarity compared to plasma. Isotonic fluids have an 
osmolarity that is similar to that of plasma (approximately 
300 mOsm/L), while hypertonic and hypotonic fluids 
have an osmolarity that is, respectively, higher and 
lower than plasma. Isotonic solutions are the most 
commonly used type of crystalloids. Hypotonic solutions 
are contraindicated during fluid resuscitation and their 
use should be reserved to treat specific conditions (e.g. 
treatment of severe electrolyte imbalances). Hypertonic 
solutions, and in particular hypertonic saline, may be useful 
in certain cases that require fluid resuscitation; a dramatic 
increase in plasma osmolarity leads to a shift of water from 
the interstitium and intracellular fluid compartments to the 
intravascular space, resulting in a transient intravascular 
volume expansion. Isotonic crystalloids available in clinical 
practice include normal saline (0.9% NaCl) and balanced 
solutions (e.g. compound sodium lactate, Hartmann’s, 
Ringer’s lactate solution, Ringer’s acetate solution, Plasma-
Lyte). Balanced solutions differ from normal saline in the 
fact that they contain electrolytes in more physiological 
concentrations, closely resembling the electrolyte 
composition of human plasma.
Shortly after administration of crystalloids most of the 
infused volume will redistribute to the interstitium and 
intracellular space and by 1 hour only 20-25% of the 
infused volume will still be within the intravascular space 
[6]. With this in mind, one can see that if intravascular 
volume expansion is the main therapeutic target, 
crystalloid fluid therapy would seem to be an inefficient 
way of achieving this and their use might promote the 
formation of interstitial oedema (Figure 2).
Colloids are high-molecular-weight compounds (molecular 
weight higher than 30 KDa) that, in the normal physiological 
condition, do not readily leave the intravascular space 
and contribute to maintaining, or possibly improving, the 
patient’s plasma oncotic pressure. Colloids are classified as 
synthetic (e.g. hydroxyethyl starches, gelatins, dextrans) 
or natural (e.g. plasma, albumin solutions, blood). The 
potential benefits of colloids include prolonged intravascular 
effect, smaller volume requirements and decreased risk 
of oedema formation when compared with crystalloids [8]. 
Therefore, if the goal of fluid administration is to address 
hypovolemia, colloids seem to present some obvious 
advantages over crystalloids. Ideal colloid solutions should 
be isotonic, iso-oncotic, rapidly degradable, inexpensive 
and have minimal side effects [9]. On first inspection, 
hydroxyethyl-starch solutions (HES) are the colloids that 
most closely match these criteria. For this reason they have 
become, up to recently, the most commonly used colloids in 
both human and veterinary medicine.
HES are synthesised from amylopectin, a highly 
branched polymer of glucose, and chemically modified 
by substitution of some hydroxyl- with hydroxyethyl- 
residues. These modifications provide some of the 
desired characteristics of colloidal fluid solutions. The 
various preparations of HES are classified based on 
their molecular weight, molar substitution (number of 
hydroxyethyl- residues per unit of glucose), pattern 
of substitution (C2:C6 ratio) and type of solutions in 
which they are suspended (e.g., balanced or unbalanced 
crystalloid solutions). Higher molecular weights and molar 
substitutions are associated with a longer half-life. Despite 
their widespread use and their perceived better safety 
profile compared to other synthetic colloids, HES use is 
associated with numerous side effects.
Undesirable side effects
Coagulopathy
Coagulopathy is one of the most common side effects 
associated with the use of synthetic colloids. The 
mechanism of this coagulopathy is not fully understood, 
Figure 2. Dog with marked interstitial oedema where fluid 
has accumulated in the extracellular fluid compartment. 
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but some of the proposed pathways include decreased 
circulating factor VIII and von Willebrand factor 
concentration, impairment of platelet function and 
interference with fibrin polymerization [10]. These effects 
have been reported in dogs as well, although the clinical 
significance of the abnormalities reported is undetermined 
[11-15]. It should be noted that current veterinary dose 
recommendations for colloids (approximately 50 ml/kg/
day for low molecular weight HES and 20 ml/kg/day for 
high molecular weight HES) are not based on efficacy 
data, but on human safety limits developed to minimise 
the risk of bleeding [8]. The coagulation disorder associated 
with HES administration appears to be proportional to 
the dose administered and the molecular weight and 
molar substitution of the molecule used. To reduce these 
risks, novel colloid solutions were developed with a lower 
molecular weight and lower degree of hydroxyethyl molar 
substitution [9]. 
Renal dysfunction
Renal dysfunction is another commonly discussed 
complication induced by colloid administration in people 
and this complication has become the focal point of 
the controversy surrounding the use of starch-based 
colloids in critically ill patients. All synthetic colloids 
undergo renal excretion and therefore have the potential 
to cause acute kidney injury (AKI). The first reports on 
colloid-induced renal failure were published in the late 
1960s in association with the use of dextrans [16,17], but 
in more recent years, the potential for inducing kidney 
damage has been reported in other colloids classes [18]. 
Several hypotheses have been formulated to explain AKI 
following colloid administration [9]. The increase in the 
intra-glomerular COP determines a decrease in glomerular 
filtration rate. The filtration of colloid molecules in the 
glomerulus increases intra-tubular viscosity and decreases 
urine flow. In addition, some molecules are re-absorbed 
by the proximal tubular epithelial cells where they induce 
vacuolar lesions. This can result in cellular swelling, with 
an additional decrease in urine flow. Renal interstitial 
inflammation has also been reported [19].
Colloids vs. crystalloids
HES solution should be theoretically less nephrotoxic given 
their biochemical characteristics. However, tubular lesions 
were noticed with the use of high-molar substitution HES 
in brain dead kidney donors [20]. Studies regarding the renal 
safety of colloids started to appear in the early 1990s[21]. 
A trend similar to that observed with coagulopathy 
appeared: the use of solutions with higher concentrations, 
higher molecular weight and molar substitution colloids 
were associated with increased risk of renal toxicity. Low 
molecular weight, molar substitution and iso-oncotic HES 
appeared to have the best safety profile [22].
Despite their theoretical advantages HES were approved 
for medical use without adequate testing regarding safety 
and efficacy [21]. Up to very recently, limited evidence 
had been in support of colloids over crystalloids for fluid 
resuscitation. A Cochrane Collaboration meta-analysis 
published in 2007 concluded that “…as colloids are not 
associated with an improvement in survival, and as they 
are more expensive than crystalloids, their use should be 
limited to randomised clinical trials” [23].
In 2008 the first large randomised clinical trial (RCT) 
comparing HES versus crystalloids for fluid resuscitation 
was published [2]. This study revealed a dose related 
effect linking HES administration with higher incidence 
of AKI, need for renal replacement therapy (a form of 
haemodialysis) and number of blood transfusions. In 2011 
numerous studies from a leading author regarding the 
safety and efficacy of starch-based colloids were retracted 
by a number of journals due to scientific misconduct and 
data fabrication [24], decreasing even further the level 
of evidence in support of HES use. The following year 
two other large high-quality RCT (6S and CHEST studies) 
investigating the use of HES versus crystalloids for fluid 
resuscitation in critically ill patients were published [3,4]. 
These studies confirmed the increased need for renal 
replacement therapy and blood transfusions associated 
with the use of HES and also showed a significant increase 
in mortality in the most severe population treated with 
HES. Based on these data the most recent Surviving Sepsis 
Guidelines [25] advised against the use of HES for the 
treatment of severe sepsis and septic shock. An updated 
Cochrane Collaboration meta-analysis published in 2013 
failed to identify any benefit of the administration of 
colloids (any) versus crystalloids, and concluded that “…
it is difficult to see how HES use can be justified in clinical 
practice.”[26] Another meta-analysis focused on the effect 
of HES on kidney function and identified an increased risk 
of developing AKI and a higher need for renal replacement 
therapy [27]. These two meta-analyses revealed that the 
risk associated with HES administration is independent 
from the type of HES or the severity of the population 
treated. As a consequence, the European Medicines 
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Agency recommended the suspension of the marketing 
authorisation for all products containing HES [28] and the 
Food and Drug Administration of the United States issued 
a warning against the use of HES in critically ill patients 
[29]. At the time of writing HES-containing solutions have 
been withdrawn from the market in several European 
countries, although the European Union has ratified a 
recommendation allowing the use of HES in some selected 
situations such as hypovolaemia not associated with sepsis 
or burns [30]. Veterinary access to HES depends on local 
medical regulatory agencies authorising the trade of these 
products. 
To date, there are no reports of nephrotoxicity induced 
by the use of HES in veterinary patients, but both renal 
lesions and renal dysfunction have been reported in 
experimental studies in dogs receiving dextran [17,31] and 
the pathophysiology of the nephrotoxicity appears to 
be similar across different classes of colloids. Although 
there is currently no evidence that HES-based colloids can 
worsen outcome in veterinary patients these fluids should 
be used cautiously, especially in patients predisposed to 
coagulopathy, AKI or with severe sepsis. Studies evaluating 
the incidence of AKI in veterinary patients treated with 
starch-based colloids are urgently needed. 
It should be noted that the cost of colloids is significantly 
higher compared to crystalloids just as they are in human 
medicine, and this aspect should not be overlooked 
when deciding what type of solution to use for fluid 
resuscitation. In the context that resuscitation with 
colloids offers no real benefits in outcome, justification for 
their use can be problematic.
Other colloid solutions are available as alternatives to HES: 
gelatins, dextrans, haemoglobin-based oxygen carriers 
(HBOC), albumin and plasma. Gelatins are derived from 
bovine collagen and have a low molecular weight (30-35 
KDa). Their immediate volume effect is similar to that of 
HES, but due to their low molecular weight they determine 
a much shorter duration of volume expansion. Compared to 
HES, the use of gelatins is associated with a higher risk of 
anaphylactic reactions [9]. There have also been concerns 
that the use of gelatins may pose a risk of inducing 
renal dysfunction, although this is not well described [9]. 
Dextrans are polysaccharides synthesised from sucrose by 
bacterial fermentation. Dextrans have the worst safety 
profile among colloids in terms of coagulopathy, renal 
dysfunction and for these reasons are not used commonly 
in human medicine. Oxyglobin® is a veterinary-specific 
stroma-free HBOC derived from bovine haemoglobin 
and licensed for the treatment of anaemia in the dog. 
Compared to other colloids, HBOC has the advantage of 
providing additional oxygen carrying capacity that can 
thereby improve tissue oxygenation. The use of HBOC has 
been demonstrated to enable more rapid achievement 
of resuscitation endpoints when compared with HES in 
both experimental and clinical veterinary studies [32,33,34]. 
However, it should be noted that HBOC has not been 
approved for human use due to safety concerns, and its use 
in veterinary patients is associated with significant side 
effects, especially in terms of volume overload [35]. Albumin 
has recently substituted HES as the most used colloid 
solution in human medicine, although there is no extensive 
evidence of a clinical benefit over crystalloids alone [25,36]. 
The use of human serum albumin in critically-ill veterinary 
patients can be associated with both immediate and 
delayed side effects [37,38]. Its use in healthy patients under 
experimental conditions was associated with sometimes 
fatal hypersensitivity reactions [39]. A canine-specific serum 
albumin had been commercially produced in North America, 
but it is no longer available. Plasma can also be used for 
fluid resuscitation and has a better safety profile compared 
to albumin solution, however, the risk of transfusion 
reactions remains. It is also important to note that plasma 
is not particularly effective as a plasma expander, nor 
is it practical as it is usually stored frozen and not cost 
effective given the need for large volumes in order to alter 
the COP of the patient.
When compared with crystalloid fluid solutions, colloids are 
considered more potent plasma expanders and this is partly 
due to their greater persistence within the intravascular 
space. This means that smaller volumes of colloids are 
required to expand the intravascular space compared with 
crystalloid solutions. The ratio of colloids:crystalloids that 
needs to be administered to achieve a similar volume 
effect is approximately 1:4, and this has been confirmed 
in several experimental studies [40,41]. An interesting finding 
that has emerged from several human RCT is that the 
actual volume effect of HES in clinical settings is less 
than previously thought. The ratio of HES to crystalloids 
administered to achieve similar resuscitation endpoints 
actually only ranged from 1:1 to 1:1.6, far below the 
predicted 1:4 ratio [2,3,4]. This raises questions on the 
validity of the assumption that colloids are more effective 
plasma expanders. This discrepancy in the volume effect 
could be explained through the concept of “context 
Controversies in fluid therapy EJCAP 24(2)  P 19
permeability. This structure can be damaged in several 
conditions, such as hypoalbuminaemia, sepsis, hypoxia, 
hyperglycaemia or hypervolemia. When the EGL is intact 
vascular permeability is preserved and colloids have a 
volume effect that exceeds that of crystalloids. However, 
damage to this structure leads to an increase in vascular 
permeability and consequently a loss of the “volume 
advantage” offered by the colloids.
Are crystalloids safe?
Given the side effects associated with the use of colloids, 
crystalloids are expected to continue to play a major 
role in human fluid resuscitation despite the higher risk 
of interstitial oedema. Sodium chloride (0.9% Saline) 
has historically been the most used solution for volume 
expansion in human patients. However, due to its 
composition, the use of 0.9% saline is associated with 
the development of hyperchloraemic metabolic acidosis 
[45]. When compared to balanced crystalloids solutions 
(e.g. lactated Ringer, Plasma-Lyte, Compounded Sodium 
Lactate), 0.9% saline use is associated with a higher 
morbidity and mortality [46,47,48]. The role of chloride-load 
and hyperchloraemic metabolic acidosis in veterinary 
critical illness is unknown, but it seems prudent to prefer 
the use of balanced crystalloids over saline for fluid 
resuscitation.
An alternative to isotonic crystalloids for fluid 
resuscitation is hypertonic saline. These solutions contain 
a higher percentage of sodium chloride of 7.2% and 
23.4%. As such they have a very high osmolarity and once 
infused produce an elevation in intravascular sodium. This 
in turn creates a concentration gradient that drives fluids 
from the interstitial and intracellular to the intravascular 
space with a short lived (20-30 minutes) intravascular 
volume expansion. The theoretical advantage is achieving 
fluid resuscitation whilst infusing a smaller volume of fluid. 
The displacement of fluid from the interstitium might also 
play a role in the treatment of traumatic brain injury. The 
use of hypertonic saline requires adequate intracellular 
and interstitial hydration and can cause bradycardia and 
hypernatremia as possible complications [5]. The safety 
and efficacy of hypertonic saline has not been established 
in human medicine and results of preliminary studies are 
contradictory [43].
Along this qualitative toxicity a quantitative toxicity has 
also been described. A positive fluid balance is associated 
sensitivity.” This concept proposes that the volume effect 
of administered fluid is variable and depends on the 
cardiovascular context of the patient. The cardiovascular 
context takes into account derangements in vascular 
permeability, intravascular volume and hydration status. 
In other words, the highly desirable behaviour of colloids 
may only be apparent in subjects with normal vascular 
endothelium and these advantages may not be appreciated 
in critically ill patients [42,43]. 
Lending support to the aforementioned concept, a major 
advancement in the understanding of fluid homeostasis 
has been made possible by the recent characterisation of 
the endothelial glycocalyx layer (EGL) (Figure 3) [44]. This 
is an active interface between the blood and the capillary 
wall and appears to be the main determinant of vascular 
Figure 3: Endothelial glycocalyx layer in health (A) and 
damaged by disease (B). The integrity of the endothelial 
glycocalyx layer may dictate the permeability of membranes 
and may explain why there are differences in the response to 
colloid fluid therapy depending on the state of the animal. 
From N Engl J Med, Myburgh GA, Mythen MG. Resuscitation 
fluids. 369:1244. Copyright © (2013) Massachusetts Medical 
Society. Reprinted with permission from Massachusetts 
Medical Society
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PPV in veterinary practice is limited by the need to place 
an arterial catheter, a procedure that can be technically 
challenging, especially in small or collapsed patients, 
and carries a risk of bleeding and infection. Moreover, 
only some monitors support algorithms that allow the 
measurement of PPV. The application of an early goal-
directed haemodynamic optimisation protocol has been 
recently described in dogs undergoing surgery for pyometra 
[57]. Further studies are needed to identify the ideal end-
points of resuscitation and if a goal-directed protocol 
would improve the outcome in veterinary patients.
Conclusions
Current evidence in human medicine suggest that the use 
of colloids over crystalloids carries very little benefit, with 
the potential of significant side effects associated with the 
use of synthetic colloids. Experimental veterinary studies 
show theoretical advantages of colloids, but these effects 
have not proven to be associated with an improvement 
in outcome. Moreover, although the nephrotoxic effects 
of HES have not yet been observed in veterinary patients, 
the mechanisms of toxicity seem to be similar across all 
synthetic colloid classes, independent of their composition, 
concentration and molecular size. Further studies will be 
needed to assess the safety profile of synthetic colloids 
in veterinary patients. In the meantime, we believe that 
a precautionary principle should be applied to colloid 
administration in veterinary patients, and their use should 
be limited to selected circumstances. Synthetic colloids 
should be used with particular caution in critically ill 
patients with sepsis or an established acute kidney injury.
In conclusion, all fluids should be considered as drugs, and 
as such have the potential to cause toxicity if administered 
incorrectly. Context sensitivity appears essential in 
the selection process of fluid type, dose, and timing of 
administration. Fluid resuscitation protocols will therefore 
have to be tailored based on the clinical status of each 
individual patient. Veterinary research should focus on the 
identification of criteria for patients’ stratification in order 
to develop individualised fluid resuscitation plans.
The authors declare no conflict of interests.
 
with the development of interstitial oedema and worse 
outcome [49]. In a trial comparing restrictive versus liberal 
fluid strategies, the latter has been associated with a 
reduced morbidity [50]. As we will see in the next paragraphs 
clinical research is focusing on methods to identify the 
adequate dose of fluid to administer. 
How much fluid to give?
A variety of strategies have been developed to optimise 
tissue perfusion in critically ill patients and have been 
collectively defined as goal-directed therapies. The 
application of goal-directed therapy protocols has shown 
to improve both morbidity and mortality in people 
[51]. Restoring and maintaining an adequate circulating 
blood volume is considered the most important aspect in 
goal-directed therapy, however identifying the adequate 
fluid dose for each individual patient is not an easy 
task. Insufficient fluid resuscitation will be associated 
with inadequate tissue perfusion, but excessive fluid 
administration will also have negative consequences 
through the development of interstitial oedema, leading to 
organ dysfunction [52]. Therefore, identifying those patients 
that will benefit from fluid administration is essential. 
This concept is referred to as fluid responsiveness, and 
is defined as the ability of a patient’s cardiac output 
to improve following the administration of intravenous 
fluid therapy. Historically fluid-responsiveness was 
assessed through “static” indexes of cardiac preload (e.g. 
central venous pressure), but such markers appear to be 
inadequate [53]. For this reason, a new approach using 
“dynamic” indexes has been developed and is based on 
evaluating the effect of changes in cardiac preload on the 
cardiac output [54]. An example of a dynamic index of fluid 
responsiveness evaluated in veterinary patients is pulse 
pressure variability (PPV) [54]. Arterial pulse pressure is used 
as a surrogate marker of stroke volume and its variation is 
assessed in patients undergoing mechanical ventilation. 
Due to lung-heart interactions, each respiratory cycle 
decreases preload in a predictable manner and this causes 
a decrease in cardiac output proportional to the patient 
“fluid-dependency.” Therefore, patients that will benefit 
from fluid administration will have a proportionally higher 
PPV. This index has been validated in dogs [55,56]. The use of 
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